Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
endocrine system diseases | D004700 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BYETTA | AstraZeneca | N-021773 RX | 2005-04-28 | 2 products, RLD, RS |
BYDUREON BCISE | AstraZeneca | N-209210 RX | 2017-10-20 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
bydureon bcise | New Drug Application | 2023-05-04 |
byetta | New Drug Application | 2022-12-21 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Expiration | Code | ||
---|---|---|---|
EXENATIDE SYNTHETIC, BYDUREON, ASTRAZENECA AB | |||
2025-01-22 | PED | ||
2024-07-22 | NPP | ||
EXENATIDE SYNTHETIC, BYDUREON BCISE, ASTRAZENECA AB | |||
2025-01-22 | PED | ||
2024-07-22 | NPP | ||
EXENATIDE SYNTHETIC, BYDUREON PEN, ASTRAZENECA AB | |||
2025-01-22 | PED | ||
2024-07-22 | NPP | ||
EXENATIDE SYNTHETIC, BYETTA, ASTRAZENECA AB | |||
2024-11-04 | M-232 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Exenatide Synthetic, Bydureon Bcise, Astrazeneca Ab | |||
8895033 | 2030-10-04 | DP | U-2589, U-2590, U-2597, U-2601, U-2602, U-3188, U-3189, U-3190 |
Exenatide Synthetic, Bydureon, Astrazeneca Ab | |||
8721615 | 2030-01-18 | DP | |
8998876 | 2030-01-07 | DP | |
8690837 | 2029-05-19 | DP | |
8827963 | 2029-02-04 | DP | |
8439864 | 2028-03-25 | DP | |
9320853 | 2028-03-25 | DP | |
8361972 | 2028-03-21 | U-2588 | |
8216180 | 2028-01-12 | DP | |
8758292 | 2027-11-12 | DP | |
8501698 | 2027-06-20 | DP | U-2588 |
8329648 | 2026-08-18 | U-2588, U-2589, U-2590, U-2593, U-2594, U-2595, U-2596, U-3188, U-3189, U-3190 | |
8906851 | 2026-08-18 | U-2588, U-2589, U-2590, U-2593, U-2597, U-3188, U-3189, U-3190 | |
9884092 | 2026-08-18 | U-2588, U-2589, U-2590, U-2593, U-2594, U-2595, U-2596, U-2597, U-3188, U-3189, U-3190 | |
6515117 | 2025-10-04 | DS, DP | U-2588 |
7456254 | 2025-06-30 | DP | U-2588, U-2589, U-2590, U-3188, U-3189, U-3190 |
7612176 | 2025-04-13 | DP | U-2588, U-2589, U-2590, U-3188, U-3189, U-3190 |
8431685 | 2025-04-13 | DP | U-2588, U-2589, U-2590, U-2597, U-3188, U-3189, U-3190 |
8461105 | 2025-04-13 | DP | U-2588, U-2589, U-2590, U-2597, U-3188, U-3189, U-3190 |
7563871 | 2024-04-15 | DP | |
9238076 | 2024-04-15 | DP | U-2588, U-2589, U-2590, U-2597, U-2599, U-3188, U-3189, U-3190 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 22 | 23 | 68 | 50 | 48 | 205 |
Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 9 | 9 | 10 | 7 | 37 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 4 | 7 | 2 | 2 | 6 | 19 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 4 | 8 | 3 | 3 | 2 | 16 |
Healthy volunteers/patients | — | — | — | 7 | — | — | 3 | 3 | 13 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 2 | 2 | 4 | — | 7 |
Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 7 | — | 7 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | — | 4 | — | 5 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | 1 | 3 | 4 |
Overweight | D050177 | — | E66.3 | 1 | 1 | — | 2 | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 5 | 1 | — | — | 7 |
Hypoglycemia | D007003 | HP_0001943 | E16.2 | 3 | 3 | 1 | — | 1 | 5 |
Craniopharyngioma | D003397 | — | — | — | 1 | 1 | — | — | 2 |
Morbid obesity | D009767 | EFO_0001074 | — | — | 2 | 1 | — | — | 2 |
Weight loss | D015431 | HP_0001824 | — | — | — | 1 | — | 1 | 2 |
Pediatric obesity | D063766 | — | — | — | — | 1 | — | — | 1 |
St elevation myocardial infarction | D000072657 | — | — | — | — | 1 | — | — | 1 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
Left ventricular dysfunction | D018487 | — | — | — | — | 1 | — | — | 1 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Insulinoma | D007340 | — | — | 5 | 1 | — | — | 1 | 6 |
Congenital hyperinsulinism | D044903 | — | — | 2 | 1 | — | — | 1 | 3 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | 2 | 1 | — | — | — | 3 |
Smoking cessation | D016540 | EFO_0004319 | — | 2 | 2 | — | — | — | 3 |
Ischemic stroke | D000083242 | — | — | — | 2 | — | — | — | 2 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | 1 | 2 |
Cocaine-related disorders | D019970 | — | F14 | 2 | 1 | — | — | — | 2 |
Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | 1 | 1 | — | — | — | 1 |
Multiple system atrophy | D019578 | — | — | — | 1 | — | — | — | 1 |
Septic shock | D012772 | — | A48.3 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | 1 | 2 |
Nesidioblastosis | D046768 | EFO_0007318 | E16.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperinsulinism | D006946 | HP_0000842 | E16.1 | — | — | — | — | 3 | 3 |
Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | — | — | 2 | 2 |
Papillary thyroid cancer | D000077273 | — | — | — | — | — | — | 1 | 1 |
Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
Aortic valve disease | D000082862 | — | — | — | — | — | — | 1 | 1 |
Cardiogenic shock | D012770 | — | R57.0 | — | — | — | — | 1 | 1 |
Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | — | 1 | 1 |
Coma | D003128 | HP_0001259 | R40.2 | — | — | — | — | 1 | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | — | 1 | 1 |
Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | — | — | 1 | 1 |
Drug common name | Exenatide |
INN | exenatide |
Description | EXENATIDE |
Classification | Protein |
Drug class | peptides |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |
PDB | — |
CAS-ID | 141758-74-9 |
RxCUI | — |
ChEMBL ID | CHEMBL414357 |
ChEBI ID | — |
PubChem CID | 16157882 |
DrugBank | DB01276 |
UNII ID | 9P1872D4OL (ChemIDplus, GSRS) |